All In Biotech

BLA 761097 · Regeneron Pharmaceuticals

Libtayo

Cemiplimab-Rwlc · Intravenous

NovelBreakthrough therapyAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Sep 28, 2018

Approved uses

11

Original approval plus efficacy supplements

Registered trials

221

19 Phase 3, 87 recruiting

FAERS reports

2,083

1,728 serious, 438 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation. ( 1.1 , 14.1 ) Basal Cell Carcinoma (BCC) for the treatment of adult patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) 1.1 Cutaneous Squamous Cell Carcinoma LIBTAYO is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. LIBTAYO is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence [see Clinical Studies (14.1) ]...

Mechanism: Binding of the PD-1 ligands PD-L1 and PD-L2 to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Cemiplimab-rwlc is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LIBTAYO · CEMIPLIMAB-RWLC 350MG · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cemiplimab" as an intervention, any sponsor and status, largest first.

All 221 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death176
  • disease progression155
  • off label use107
  • fatigue88
  • rash86
  • dyspnoea65
  • pyrexia64
  • pruritus53
  • interstitial lung disease50
  • myocarditis50
  • asthenia47
  • drug ineffective47

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20187
2019138
2020105
2021204
2022292
2023258
2024345
2025435
2026299

Recalls

1 FDA enforcement reports for this application.

  • Jul 28, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Libtayo (Cemiplimab-Rwlc)

2024 spending

$12.6M

Beneficiaries

212

1,232 claims

Per beneficiary

$59,295

$1,458.64 per unit

View as table
YearSpending
2020$1,875,102
2021$1,897,142
2022$2,697,847
2023$5,887,092
2024$12,570,559

Part B: Libtayo (Cemiplimab-Rwlc) · HCPCS J9119

2024 spending

$348M

Beneficiaries

5,482

35,522 claims

Per beneficiary

$63,500

2024 ASP limit $27.74 per unit

View as table
YearSpending
2020$155,476,305
2021$179,470,041
2022$203,832,304
2023$270,188,134
2024$348,106,559

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 111 on PubMed

Sponsor: Regeneron

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.